LOXL2 and Hepatic fibrosis: Although the failure of ASK1 and LOXL2 inhibitors, which were once thought to be promising, in phase 3 clinical studies were disappointing to developers, recent clinical trials have demonstrated that several candidates such as FGF21 analogues, FASN inhibitors, pan-PPAR agonists, GLP-1R agonists, GCG/GLP-1R agonists, hydronidone, etc. can improve biopsy-based hepatic fibrosis, which represents a new hope for antifibrotic therapy.